In our cohort of 170 WGS, we observed PPM1D mutations in 8% of all gliomas (14/170) and 11% of DMG (12/110), with enrichment in DMGs (11/91, Fisher’s exact test, P = 0.056) (Fig. 1A), and confirmed their anti-correlation with TP53 mutations (Fisher’s exact test, P < 0.0001) (Supplementary Fig. 1A). Here, PPM1D is linked to central nervous system cancer.